1. Generics Bulletin
  2. >>Business

Endo And Mallinckrodt Plan To Merge - And Spin Off Generics Business

CEO Siggi Olafsson Will Lead The Combined Firm

 
• By Joseph Haas

Both vexed by bankruptcies and opioid litigation, Endo and Mallinckrodt will merge in a deal valued at $6.7bn. The new company will spin out its generics and sterile injectable business.

Company merger
The Endo/Mallinckrodt combination is valued at an estimated $6.7bn • Source: Shutterstock

Two companies of similar economic scale and each with its own troubled financial history revealed plans to merge on 13 March, as privately held Mallinckrodt and publicly traded Endo will combine into a specialty pharma expected to yield $3.6bn in pre-tax earnings in 2025. Both have survived recent bankruptcy filings and lawsuits related to the opioid crisis in getting to this milestone.

In tandem with the stock-and-cash merger expected to close during the second half of 2025 and valued at $6

Key Takeaways
  • Endo and Mallinckrodt announced a planned merger valued at $6.7bn.
  • Both companies share a recent history of filing for bankruptcy and owing court-ordered payouts related to the sale of opioid drugs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Products

Hikma Eyes $5bn Sales Target As It Sets Out Plans To 2030

 
• By Dave Wallace

Unveiling a new name for its generics business, Hikma has at the same time set out medium-term financial goals for its business that include three-year growth objectives for its sales and profits, as well as aiming at a $5bn turnover target by 2030.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

Gedeon Richter: General Medicines Unit Deserves ‘More Attention And Credit’

 
• By Dean Rudge

Gedeon Richter’s CEO has urged analysts and the firm itself to give more attention to its “unfairly neglected” General Medicines division – which includes both generics and licensed-in innovative products – during the Hungarian firm’s first-quarter earnings call.